In response to the need for novel treatments for infectious diseases, our laboratory has been developing a radioimmunotherapy (RIT) approach (reviewed in reference 4). Cryptococcus neoformans, our model organism, has well-characterized antibody reagents and animal models. We previously reported that the survival of A/JCr mice systemically infected with 10 5 C. neoformans cells was significantly prolonged by treatment with beta emitter 188-rhenium ( 188 Re)-or alpha emitter 213-bismuth ( 213 Bi)-labeled monoclonal antibody (MAb) 18B7, which recognizes the polysaccharide capsule of C. neoformans (5) . Clinically, patients present at different stages of infection, some with high microbial burdens for which the efficacy of RIT is unknown. Another question is whether RIT selects for radiation-resistant fungal cells, which would interfere with follow-up RIT.
We hypothesized that 188 Re, which has a 16.9-h physical half-life, would be more likely than 213 Bi (46-min half-life) (1) to deliver radioactivity carried by MAb 18B7 (3) to 10 6 C. neoformans cells (strain 24067; ATCC, Manassas, VA). Our animal experiments followed the guidelines of the Albert Einstein College of Medicine Institute for Animal Studies. Groups of five A/JCr mice (NCI; Bethesda, MD) were infected i.v. with 10 6 C. neoformans cells and treated intraperitoneally 24 h later with 100 to 200 Ci of 188 Re-18B7 (30 g MAb per mouse) or 30 g of unlabeled 18B7. A/JCr mice were used because they are highly susceptible to i.v. infection, possibly due to a partial complement deficiency (9) . Infection with 10 6 C. neoformans cells delivers a high inoculum that translates into a high organism burden and increased levels of glycoronoxylomannan (GXM), as would be expected in an established infection. In fact, even in infections with 10 5 cells, the levels of GXM in the blood of A/JCr mice are equal to those in patients with cryptococcosis (5). Kaplan-Meyer plots (Fig. 1a) showed that all doses of 188 Re-18B7 significantly (P Ͻ 0.05) prolonged survival; 125 and 150 Ci were most effective, and 200 Ci was least effective. These doses should deliver radiation to any C. neoformans cells in the host that can be accessed by a labeled antibody. There would be 8 ϫ 10 9 C. neoformans cells 24 h after infection with 10 6 cells; 100 Ci 188 Re contain 3.2 ϫ 10 11 atoms, at least 50 radioactive atoms per C. neoformans cell. This study with mice systemically infected with 10 6 C. neoformans cells demonstrates that RIT can reduce mortality even with high fungal burdens. Previously, we reported decreased fungal burdens in lungs and brains following treatment with 188 Re (5), where the survival rate of mice infected with 10 5 C. neoformans cells was the highest in the group treated with 100 Ci, while the organ fungal burden was the lowest for those treated with 200 Ci. There is no linear dose response in RIT in general (reviewed in reference 8), and with the increased infection burden the therapeutic window seems to narrow. Hematologic toxicity at the high end of the dose curve seems to outweigh the therapeutic benefit of reduction of the fungal burden by high doses (7) .
A second goal was to evaluate the retention of RIT sensitivity in C. neoformans cells isolated from RIT-treated mice. The emergence of radiation-resistant cells would be a concern for subsequent RIT and the therapeutic outcome. (Fig. 1b and c) . To evaluate the possibility that RIT might select for C. neoformans cells resistant to radiation in vivo, we infected A/JCr mice with CN Re RIT , CN Bi RIT , and CN naive cells. Infected mice were treated with 150 Ci 188 Re-18B7 or 125 Ci 213 Bi-18B7 24 h post-i.v. infection and then monitored for survival and weight loss. We detected no differences in weight loss for mice infected with CN naïve cells and mice infected with CN Re RIT or CN Bi RIT cells. All groups lost weight after infection ( Fig. 1d and e) ; however, mice receiving RIT with 213 Bi-18B7 lost significantly less weight at the nadir (27 to 30 days) than untreated controls (P Ͻ 0.007 by Student's t test) (Fig.  1d) . By contrast, the trend for groups treated with 188 Re-18B7 was to lose more weight than untreated groups (P ϭ 0.06) (Fig.  1e) . RIT with 188 Re-18B7 was more radiotoxic in mice with (Fig. 1f) . The survival of mice treated with 213 Bi-18B7 MAb was longer (P ϭ 0.04) than of those treated with 188 Re-18B7 (Fig. 1g) , probably due to the higher killing power of alpha particles from 213 Bi than of electrons from 188 Re.
At 130 days postinfection, the lungs and brains from selected mice from each group were plated for CFU or analyzed histologically for signs of inflammation, possible radiation scarring (by using hematoxylin and eosin stain), and the presence of C. neoformans cells (by using Gomori methenamine-silver nitrate stain [GMS] ). No striking difference between the groups was evident. The pathology in these chronically infected mice was generally focal and circumscribed, consisting of areas of lymphocytic and histiocytic infiltrates in areas containing cryptococcal cells (Fig. 2) . Organ cultures from some mice from each treatment group had no CFU, consistent with the clearance of infection in both the brain and lung. Radiation fibrosis in the lungs was nonexistent (Fig. 2) , consistent with previous observations (7) .
Treatment of C. neoformans with particulate radiation leads to the loss of clonogenicity (6, 2), which would explain the absence of radiation-resistant phenotypes after RIT. The residual cells which replicate after RIT most likely were protected from radiolabeled antibodies by a biofilm, an abscess, or a host cell. Like other antifungal therapies, RIT reduces the cryptococcal burden but does not eradicate infection. The efficacy of RIT might be enhanced by combining it with antifungal drugs or by repeated fractionated treatments. RIT provides a novel approach to antifungal therapy, potentially applicable to a wide spectrum of human mycoses. 
